RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Neuro, >>> predicating terms of the agreement upon a specific valuation for Cortex <<<



Another possibility might be that the partner also has interest in SA, and with only one clinic-ready compound available (CX-1739), they're waiting for the SA results prior to finalizing plans for ADHD. Or perhaps with Schizo and Depression now suddenly available for partnering, the scope of discussions have broadened, and the partner is rethinking whether or not ADHD should be their primary focus.